Elizabeth A. Mittendorf, MD, PhD
The role of neoadjuvant therapy for patients with HER2-positive breast cancer continues to evolve, including ongoing efforts to determine which patients are likely to respond to the early treatment.
In an interview with OncLive, Elizabeth A. Mittendorf, MD, PhD, an associate professor in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center, discussed the evolving neoadjuvant treatment landscape and other developments in the field of HER2-postive breast cancer.
OncLive: Please discuss the advancements with neoadjuvant therapy in HER2-positive breast cancer.
Mittendorf: I would contend that most of us believe patients with HER2-positive breast cancer, particularly those who meet the criteria to receive pertuzumab in the neoadjuvant setting, would prefer that systemic therapy administered upfront.
... to read the full story